Analysts Offer Insights on Healthcare Companies: Incyte (NASDAQ: INCY) and Jazz Pharmaceuticals (NASDAQ: JAZZ)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Incyte (INCYResearch Report) and Jazz Pharmaceuticals (JAZZResearch Report).

Incyte (INCY)

In a report released today, Brian Abrahams from RBC Capital maintained a Hold rating on Incyte, with a price target of $86.00. The company’s shares closed last Wednesday at $69.59, close to its 52-week low of $69.42.

According to TipRanks.com, Abrahams is a 3-star analyst with an average return of 3.7% and a 47.3% success rate. Abrahams covers the Healthcare sector, focusing on stocks such as Intra-Cellular Therapies, Karyopharm Therapeutics, and Vertex Pharmaceuticals.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Incyte with a $97.13 average price target, a 32.8% upside from current levels. In a report released yesterday, Mizuho Securities also assigned a Hold rating to the stock with a $95.00 price target.

See today’s analyst top recommended stocks >>

Jazz Pharmaceuticals (JAZZ)

In a report released today, Ami Fadia from Needham initiated coverage with a Buy rating on Jazz Pharmaceuticals and a price target of $220.00. The company’s shares closed last Wednesday at $129.55, close to its 52-week low of $127.80.

According to TipRanks.com, Fadia is a 1-star analyst with an average return of -0.4% and a 43.8% success rate. Fadia covers the Healthcare sector, focusing on stocks such as Harmony Biosciences Holdings, Intra-Cellular Therapies, and Avadel Pharmaceuticals.

Jazz Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $213.63.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.